BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:ALS Association  - Drug Development Program
DTSTART;VALUE=DATE:20231218
DTSTAMP:20260406T230507Z
UID:3ecef6adab7bc1a43a1530b0a3ace46400a359fbb489787c997b06a2
CATEGORIES:Call for proposal
DESCRIPTION:This program leverages academic scientific expertise along wit
 h industry know-how to drive the crucial transition from laboratory resear
 ch project to industry drug development effort. This stage in the drug dev
 elopment pipeline is often underfunded because it is too late for traditio
 nal academic funding mechanisms and too early for most industry funding me
 chanisms. By supporting projects at this stage\, the program helps fill th
 is funding gap and has contributed to the expansion of companies and thera
 peutics entering ALS clinical trials.\n\nDuration:\n\n	2 years\n\n\nFundin
 g:\n\n\n	$500\,000 to support the preclinical assessment of novel or repur
 posed therapeutics for ALS\n\n\nEligibility:\n\n\n	Open to researchers wor
 king in industry or at academic institutions worldwide.\n	Applicants shoul
 d have already selected the lead therapeutic candidate they would like to 
 test as this funding opportunity aims to support programs that have a high
  probability of entering the clinic within 3 years\n\n\nHow to Apply: All 
 application materials must be submitted through the online grants manageme
 nt platform ProposalCentral. To find this funding opportunity on ProposalC
 entral\, navigate to the Grant Opportunities tab and search for Grant Make
 r: The ALS Association.\n\nApplication Deadline:\n\n\n	- Letter of Intent 
 due on 18 December\, 5 pm US ET\n	- Full Proposal (by invitation only) due
  on 7 March 2024\n\n\nFurther information:\n\n\n	More information about th
 e program is available here.\n	LOI should be submitted though ProposalCent
 ral\n	For any other questions\, please contact the Research Office\n\n\n\n
 	 \n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR